Seegene, Inc. Stock

Equities

A096530

KR7096530001

Biotechnology & Medical Research

End-of-day quote Korea S.E. 06:00:00 2024-04-16 pm EDT 5-day change 1st Jan Change
21,000 KRW 0.00% Intraday chart for Seegene, Inc. -6.67% -8.30%
Sales 2024 * 401B 290M Sales 2025 * 471B 340M Capitalization 967B 698M
Net income 2024 * 41B 29.6M Net income 2025 * 69B 49.82M EV / Sales 2024 * 2.41 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.05 x
P/E ratio 2024 *
26.4 x
P/E ratio 2025 *
15.7 x
Employees 63
Yield 2024 *
3.81%
Yield 2025 *
3.81%
Free-Float 57.91%
More Fundamentals * Assessed data
Dynamic Chart
Seegene, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Seegene Inc. Announces Collaboration with Microsoft to Realize a World Free from All Diseases CI
Microbix and Seegene USA Jointly Enhancing Lab Test Accuracy; Expanded Collaboration Aims To Improve Syndromic Infectious Disease Testing MT
Microbix Brief: Microbix and Seegene USA Jointly Enhancing Lab Test Accuracy MT
Seegene, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on July 13, 2023. CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on February 28, 2023. CI
Seegene, Inc.'s Equity Buyback announced on February 28, 2023, has expired with 2,046,354 shares, representing 4.11% for KRW 49,998.4 million. CI
Seegene, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Seegene Inc. Unveils Solutions to Popularize Molecular Diagnostics At 2023 AACC CI
Seegene, Inc. announces an Equity Buyback for KRW 30,000 million worth of its shares. CI
Seegene, Inc. authorizes a Buyback Plan. CI
Seegene, Inc. and Werfen Partner to Collaborate on Onesystem Business to Develop Syndromic qPCR Assays CI
Seegene and Werfen Partner to Collaborate on OneSystem(TM) Business to Develop Syndromic qPCR Assays CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on February 28, 2023. CI
More news
1 day-3.67%
1 week-6.67%
Current month-12.68%
1 month-13.22%
3 months-9.87%
6 months+3.19%
Current year-8.30%
More quotes
1 week
20 950.00
Extreme 20950
22 900.00
1 month
20 950.00
Extreme 20950
27 400.00
Current year
20 950.00
Extreme 20950
30 600.00
1 year
19 040.00
Extreme 19040
30 600.00
3 years
19 040.00
Extreme 19040
116 400.00
5 years
9 525.00
Extreme 9525
161 100.00
10 years
7 225.00
Extreme 7225
161 100.00
More quotes
Managers TitleAgeSince
Founder 66 00-09-15
President 65 -
President 70 -
Members of the board TitleAgeSince
Founder 66 00-09-15
Director/Board Member 77 -
Director/Board Member 61 10-03-21
More insiders
Date Price Change Volume
24-04-16 21,000 0.00% 154 509
24-04-16 21,000 -3.67% 236,424
24-04-15 21,800 -1.36% 202,621
24-04-12 22,100 -0.90% 193,848
24-04-11 22,300 -0.89% 204,765

End-of-day quote Korea S.E., April 15, 2024

More quotes
Seegene Inc is a Korea-based company engaged in the development, manufacturing and distribution of molecular diagnostic reagents. The Company mainly provides infectious pathogens inspection products, including allergic respiratory pathogens, sexually transmitted diseases pathogens, human papilloma virus (HPV) and other inspection products, drug resistance inspection products, single nucleotide polymorphisms (SNP) inspection products, as well as somatic mutation cancer inspection products. In addition, it is involved in the provision of automatic real-time detection instruments. The Company provides its products under the brand names of Seeplex, Anyplex and Magicplex. The Company distributes its products within domestic market and to overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
21,000 KRW
Average target price
25,000 KRW
Spread / Average Target
+19.05%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. A096530 Stock